Benzamide;9-oxa-4-thia-2-azatricyclo[4.4.0.01,3]decane

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: Benzamide;9-oxa-4-thia-2-azatricyclo[4.4.0.01,3]decane
• 英文别名: benzamide;9-oxa-4-thia-2-azatricyclo[4.4.0.01,3]decane
• 化学式: C14H18N2O2S
• 分子量: 278.37
• InChiKey: LFSKHMMYBXDCLH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.22
• 重原子数：
  19
• 可旋转键数：
  1
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  99.6
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• [EN] N-[2-(2-AMINO-6,6-DISUBSTITUTED-4, 4A, 5, 6-TETRAHYDROPYRANO [3,4-D][1,3] THIAZIN-8A (8H)-YL) -1, 3-THIAZOL-4-YL] AMIDES<br/>[FR] N-[2-(2-AMINO-6,6-DISUBSTITUÉS-4,4A,5,6-TÉTRAHYDROPYRANO[3,4-D][1,3]THIAZIN-8A(8H)-YL)-1,3-THIAZOL-4-YL]AMIDES
  申请人：PFIZER

  公开号：WO2017051276A1

  公开（公告）日：2017-03-30

  The present invention is directed to compounds, tautomers and pharmaceutically acceptable salts of the compounds which are disclosed, wherein the compounds have the structure of Formula (I), and the variables R1, R2 and R3 are as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

  本发明涉及所披露的化合物、互变异构体和该化合物的药用可接受盐，其中所述化合物具有式（I）的结构，变量R1、R2和R3如规范中所定义。还披露了相应的药用组合物、治疗方法、合成方法和中间体。
• HETEROARYL-SUBSTITUTED HEXAHYDROPYRANO [3,4-d][1,3]THIAZIN-2-AMINE COMPOUNDS
  申请人：Pfizer Inc.

  公开号：EP2956458A1

  公开（公告）日：2015-12-23
• N-[2-(2-AMINO-6,6-DISUBSTITUTED-4, 4A, 5, 6-TETRAHYDROPYRANO [3,4-D][1,3]THIAZIN-8A (8H)-YL) -1, 3-THIAZOL-4-YL]AMIDES
  申请人：Pfizer Inc.

  公开号：EP3353183A1

  公开（公告）日：2018-08-01
• [EN] HETEROARYL-SUBSTITUTED HEXAHYDROPYRANO [3,4-d][1,3] THIAZIN-2-AMINE COMPOUNDS<br/>[FR] COMPOSÉS HEXAHYDROPYRANO [3,4-D][1,3] THIAZIN-2-AMINE SUBSTITUÉS PAR UN HÉTÉROARYLE
  申请人：PFIZER

  公开号：WO2014125394A1

  公开（公告）日：2014-08-21

  The present invention is directed to compounds, tautomers and pharmaceutically acceptable salts of the compounds which are disclosed, wherein the compounds have the structure of Formula I, and the variables R1 and R2 are as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.